Biotechnology

Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published

SUZHOU, China, March 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that the study ...

2023-03-03 14:56 3769

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further ...

2023-03-02 19:15 5120

DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY

Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), an independent Swiss-based, biopharmaceutical company ...

2023-03-02 09:00 3746

ClinChoice Acquires CROMSOURCE, Expanding its Global Presence

PHILADELPHIA, SHANGHAI and VERONA, Italy, March 2, 2023 /PRNewswire/ -- ClinChoice Medical Development is pleased to announce its acquisition of CROMSOURCE S.r.l., an ISO-certified full-service contract research organization with its corporate headquarters inVerona, Italy and its US headquarters ...

2023-03-02 04:12 4445

Cambrex Recognized with CDMO Leadership Awards for 9th Consecutive Year

EAST RUTHERFORD, N.J., March 1, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized with 2023 CDMO Leadership Awards in the categories of Quality, Service, Expertise, and Compatibility. Additionally...

2023-03-01 19:00 3161

A promising picture for multi-cancer early detection in Southeast Asia - latest update from biotech firm Gene Solutions

HO CHI MINH CITY, Vietnam, March 1, 2023 /PRNewswire/ -- In January 2023, Vietnam's Medical Genetics Institute & Gene Solutions  published their research paper on Cancer Investigation:Clinical validation of a ctDNA-based assay for multi-cancer detection: an interim re...

2023-03-01 09:30 3892

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of JWATM214 in patients with advanced hepato...

2023-02-28 17:30 3887

CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma

* This supplementary new drug application was filed for the fourth indication for sugemalimab inChina, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If approved, sugemalimab would be the first PD-L1 monoclo...

2023-02-28 08:05 6060

Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today held a ceremony to celebrate the initiation of operations a...

2023-02-28 07:30 6496

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. HSHKBIO selects securities of multiple listed co...

2023-02-27 17:15 4388

Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training

UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management. Turacoz is setting the standar...

2023-02-27 17:07 2313

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS * Total Group revenue $160.1M ...

2023-02-27 14:37 2803

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Today, Invivoscribe announced that its Shanghai lab in China has received CAP accreditation. The College of American Pathologists (CAP) is a professional organization that accredits clinical laboratories across the world. The CAP accreditation process is ...

2023-02-23 22:00 3550

Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymp...

2023-02-23 15:02 2316

World-renowned therapist and wellness expert Marisa Peer endorses natural prebiotic Kfibre & Kfibre Pro Synbiotics for advanced gut health management.

Heal the Gut, Heal the Mind  SYDNEY, Feb. 23, 2023 /PRNewswire/ -- As a pioneering therapist, speaker, best-selling author, and the founder of Rapid Transformational Therapy (RTT®), Marisa's guiding ethos is centred on simple steps that produce dramatic and life-saving results. One of those step...

2023-02-23 13:31 2694

Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901

HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudi...

2023-02-23 12:26 3396

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity...

2023-02-22 21:05 3517

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, an...

2023-02-21 23:04 4041

Synbio Tech Inc. and Cosmax Group signed an exclusive cooperation agreement to jointly expand the South Korean probiotics market

KAOHSIUNG, Taiwan, Feb. 21, 2023 /PRNewswire/ -- Synbio Tech Inc. and Cosmax NBT, a major South Korean biotechnology company officially signed an exclusive cooperation agreement to launchLactobacillus plantarum TWK10® probiotic strain inSouth Korea, and announced that TWK10® has been approved as ...

2023-02-21 16:01 4204

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces t...

2023-02-21 14:00 4550
1 ... 111112113114115116117 ... 184